256940 — Keeps BioPharma Share Price
Last trade - 00:00- KR₩214bn
- KR₩258bn
- KR₩128bn
- 19
- 15
- 97
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.38 | ||
| Price to Tang. Book | 19.71 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.72 | ||
| EV to EBITDA | 29.87 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.79% | ||
| Return on Equity | 2.07% | ||
| Operating Margin | 4.87% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 15,216.58 | 4,260.55 | 14,617.27 | 92,133.34 | 127,583.23 | n/a | n/a | 55.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Keeps BioPharma Inc, formerly KPS Corp, is a Korea-based company principally engaged in the machinery and equipment business for the manufacture of flat panel displays. The Company operates its business through three segments. The Recycling Business segment is engaged in the production and sale of recycled cartilage such as pure lead and alloy soft materials, and polypropylene (PP). The Bio Business segment produces and sells medical devices and medicines. The Organic Light Emitting Diode (OLED) Business segment is engaged in the production and sale of OLED mask tensioners and precision stages.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 4th, 2000
- Public Since
- December 21st, 2016
- No. of Shareholders
- 7,228
- No. of Employees
- 49
- Sector
- Semiconductors & Semiconductor Equipment
- Industry
- Technology
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 19,076,310
- Address
- 52, Dongtansandan 10-gil, Dongtan-myeon, HWASEONG, 18487
- Web
- http://www.kpscorp.co.kr/
- Phone
- +82 3180415411
- Auditors
- Samil Accounting Corp.
Upcoming Events for 256940
Similar to 256940
3Alogics
Korea Exchange - KOSDAQ
3S Korea Co
Korea Exchange - KOSDAQ
ABOV Semiconductor Co
Korea Exchange - KOSDAQ
ADTechnology Co
Korea Exchange - KOSDAQ
AlphaChips
Korea Exchange - KOSDAQ
FAQ
As of Today at 21:32 UTC, shares in Keeps BioPharma are trading at KR₩11,520. This share price information is delayed by 15 minutes.
Shares in Keeps BioPharma last closed at KR₩11,520 and the price had moved by +91.36% over the past 365 days. In terms of relative price strength the Keeps BioPharma share price has outperformed the FTSE Developed Asia Pacific Index by +93.55% over the past year.
The overall consensus recommendation for Keeps BioPharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreKeeps BioPharma does not currently pay a dividend.
Keeps BioPharma does not currently pay a dividend.
Keeps BioPharma does not currently pay a dividend.
To buy shares in Keeps BioPharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩11,520, shares in Keeps BioPharma had a market capitalisation of KR₩214bn.
Here are the trading details for Keeps BioPharma:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 256940
Based on an overall assessment of its quality, value and momentum Keeps BioPharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Keeps BioPharma is KR₩16,956. That is 47.19% above the last closing price of KR₩11,520.
Analysts covering Keeps BioPharma currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Keeps BioPharma. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +127.74%.
As of the last closing price of KR₩11,520, shares in Keeps BioPharma were trading +70.81% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Keeps BioPharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩11,520.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Keeps BioPharma's management team is headed by:
- Na Yeon Kim - NID